1. Home
  2. VITL vs CTNM Comparison

VITL vs CTNM Comparison

Compare VITL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vital Farms Inc.

VITL

Vital Farms Inc.

HOLD

Current Price

$9.74

Market Cap

557.9M

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$14.82

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VITL
CTNM
Founded
2007
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
557.9M
550.7M
IPO Year
2020
2024

Fundamental Metrics

Financial Performance
Metric
VITL
CTNM
Price
$9.74
$14.82
Analyst Decision
Buy
Buy
Analyst Count
11
4
Target Price
$32.00
$19.00
AVG Volume (30 Days)
1.2M
500.0K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
22.03
0.46
EPS
N/A
N/A
Revenue
$759,444,000.00
N/A
Revenue This Year
$19.72
N/A
Revenue Next Year
$17.02
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.26
N/A
52 Week Low
$7.95
$8.60
52 Week High
$49.04
$17.79

Technical Indicators

Market Signals
Indicator
VITL
CTNM
Relative Strength Index (RSI) 33.60 42.13
Support Level $7.95 $13.65
Resistance Level $10.60 $15.36
Average True Range (ATR) 0.47 0.91
MACD -0.04 -0.25
Stochastic Oscillator 2.39 2.35

Price Performance

Historical Comparison
VITL
CTNM

About VITL Vital Farms Inc.

Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: